Multiparametric Magnetic Resonance Imaging of the Prostate

Neto, Jaime Araújo Oliveira; Parente, Daniella Braz

doi:10.1016/j.mric.2013.01.004

Cited by 15 publications

(9 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In MRS, the position of each metabolite peak in the output graph reflects the resonant frequencies or chemical shifts of its hydrogen protons, and the area of each peak reflects the relative concentration of that metabolite [53]. The dominant peaks observed in prostate MRS are from protons in citrate (2.60 ppm), creatine (3.04 ppm), and choline compounds (3.20 ppm) (Figure 5) [53].…”

Section: Mr Image Acquisitionsmentioning

confidence: 99%

See 1 more Smart Citation

Computer-aided Detection of Prostate Cancer with MRI

et al. 2016

View full text Add to dashboard Cite

One in six men will develop prostate cancer in his life time. Early detection and accurate diagnosis of the disease can improve cancer survival and reduce treatment costs. Recently, imaging of prostate cancer has greatly advanced since the introduction of multi-parametric magnetic resonance imaging (mp-MRI). Mp-MRI consists of T2-weighted sequences combined with functional sequences including dynamic contrast-enhanced MRI, diffusion-weighted MRI, and MR spectroscopy imaging. Due to the big data and variations in imaging sequences, detection can be affected by multiple factors such as observer variability and visibility and complexity of the lesions. In order to improve quantitative assessment of the disease, various computer-aided detection systems have been designed to help radiologists in their clinical practice. This review paper presents an overview of literatures on computer-aided detection of prostate cancer with mp-MRI, which include the technology and its applications. The aim of the survey is threefold: an introduction for those new to the field, an overview for those working in the field, and a reference for those searching for literature on a specific application.

show abstract

Section: Mr Image Acquisitionsmentioning

confidence: 99%

“…The dominant peaks observed in prostate MRS are from protons in citrate (2.60 ppm), creatine (3.04 ppm), and choline compounds (3.20 ppm) (Figure 5) [53]. …”

Section: Mr Image Acquisitionsmentioning

confidence: 99%

Computer-aided Detection of Prostate Cancer with MRI

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The mpMRI scan offers more accurate detection in identifying areas of greater likelihood of clinically significant PCa, resulting in increased diagnosis rates. 10 This is reflected by the decrease in diagnosis of low risk PCa, and the increase in high-risk PCa. Thus, the mpMRI scan increased the threshold by which low risk cancers were identified, resulting in a reduced detection of low risk disease whilst improving the detection of high-risk PCa.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016

Carlaw

Woo

2017

Prostate International

View full text Add to dashboard Cite

BackgroundApproaches to prostate cancer (PCa) diagnosis and treatment have evolved significantly over past decades. There has been an increasing focus on minimizing overdiagnosis and overtreatment of clinically insignificant PCa. The objective of this study was to evaluate the changes in the diagnostic approach and initial treatment strategy that has evolved over time in an Australian urological private practice.Materials and methodsMen with newly diagnosed PCa were identified from the private practice electronic and paper medical records from 2005 to 2016 and data was consolidated into six groups of 2-year intervals. Diagnostic strategy was analyzed with particular reference to the use of multiparametric magnetic resonance imaging (mpMRI) scan and 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scans. National Comprehensive Cancer Network risk group stratification was correlated with initial treatment strategy and compared over time.ResultsChart review identified 839 men who had a mean age of 65.8 years. In 2011–2012, prebiopsy mpMRI scan was introduced. Its uptake correlated with a decrease in numbers of men diagnosed with low risk cancer (r = -0.80, P = 0.04) and an increase in numbers of men diagnosed with high-risk cancer (r = 0.90, P = 0.01). The use of 68Ga-PSMA PET/CT was associated with decreasing use of CT and bone scans performed. Open radical prostatectomy had a declining trend particularly when robotic surgery (robotic assisted radical prostatectomy (RARP)) was introduced. Pelvic lymph node dissections performed progressively decreased. An increased use of luteinizing hormone receptor hormone (LHRH) antagonists was seen in favor of LHRH agonists. Whilst use of high dose rate brachytherapy declined, there was an increased use of low dose rate brachytherapy.ConclusionPrebiopsy mpMRI has been associated with an increased proportion of newly diagnosed men having clinically significant PCa. Over time, 68Ga-PSMA PET/CT scans, robotic assisted radical prostatectomy (RARP) and LHRH antagonists have increased in use, whilst CT and bone scans, and pelvic lymph node dissections have decreased.

show abstract

“…The position of each metabolite peak in the output graph reflects the resonant frequencies or chemical shifts of its hydrogen protons, and the area of each peak reflects the relative concentration of that metabolite [123]. On MRS, the resonances for the prostate metabolites, such as citrate (Cit), creatine (Cre), and choline (Cho), occur at distinct frequencies (2.60, 3.04, and 3.20 ppm for Cit, Cre, and Cho, respectively).…”

Section: Multiparametric Mri For the Prostatementioning

confidence: 99%

Molecular imaging and fusion targeted biopsy of the prostate

Fei

Nieh

Master

et al. 2016

Clin Transl Imaging

View full text Add to dashboard Cite

Purpose This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.

show abstract

Multiparametric Magnetic Resonance Imaging of the Prostate

Cited by 15 publications

References 75 publications

Computer-aided Detection of Prostate Cancer with MRI

Computer-aided Detection of Prostate Cancer with MRI

Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016

Molecular imaging and fusion targeted biopsy of the prostate

Contact Info

Product

Resources

About